Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Tilray Brands Inc (TLRY) Price & Performance

GraniteShares 2x Long NVDA Daily ETFTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

GraniteShares 2x Long NVDA Daily ETF vs Tilray Brands Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $36.96 (market cap $3.56B), while Tilray Brands Inc trades at $3.53 (market cap $530.54M). The key difference: GraniteShares 2x Long NVDA Daily ETF is far larger — about 6.7× Tilray Brands Inc's market cap, and GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and Tilray Brands Inc for 31 Days on average.

NVDLTLRY
Market Cap
$3.56B$530.54M
Volume
9,740,6439,099,075
Sector
Leveraged / InverseHealth
52-Week High
$43.02$21.00
52-Week Low
$21.76$3.57
Typical Hold Time
15 Days31 Days
Enterprise Value
—$684.46M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GraniteShares 2x Long NVDA Daily ETF

NVDL (GraniteShares 2x Long NVDA Daily ETF) trades at $36.905, down 6.73% on the day, with technical indicators showing a bullish bias from moving averages but neutral oscillators. The ETF provides 2x daily leveraged exposure to NVIDIA, which continues to lead AI innovation and recently beat Q2 2027 earnings estimates. Support levels are clustered around $36-$34, with resistance at $38-$41.

While leveraged exposure to NVIDIA's AI leadership offers significant upside potential, NVDL faces risks from daily reset mechanics that can cause performance drift from long-term NVDA returns. Recent articles highlight both optimism about NVIDIA's technical breakout and concerns about the ETF's tracking efficiency. The bullish technical setup suggests near-term opportunity, but volatility remains elevated.

Tilray Brands Inc

Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.

The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NVDL
100% Buy0% Sell
Avg holding period · 15 Days
TLRY
54% Buy46% Sell
Avg holding period · 31 Days

Top news

Latest headlines on both assets

About GraniteShares 2x Long NVDA Daily ETF

NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.

Read more on NVDL →

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY →